O89100
Gene name |
Grap2 (Gads, Grb2l, Grid, Mona) |
Protein name |
GRB2-related adaptor protein 2 |
Names |
Adapter protein GRID, GADS protein, GRB-2-like protein, GRB2L, GRB-2-related monocytic adapter protein, MONA, Monocytic adapter, GRBLG, Growth factor receptor-binding protein, Hematopoietic cell-associated adaptor protein GrpL |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:17444 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
9 structures for O89100
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 1H3H | NMR | - | A | 263-322 | PDB |
| 1OEB | X-ray | 176 A | A/B | 265-322 | PDB |
| 1R1P | X-ray | 180 A | A/B/C/D | 50-147 | PDB |
| 1R1Q | X-ray | 180 A | A/B | 50-147 | PDB |
| 1R1S | X-ray | 190 A | A/C/E/G | 50-147 | PDB |
| 1UTI | X-ray | 150 A | A | 265-322 | PDB |
| 2D0N | X-ray | 157 A | A/C | 267-322 | PDB |
| 2W10 | X-ray | 190 A | A/B | 265-322 | PDB |
| AF-O89100-F1 | Predicted | AlphaFoldDB |
14 variants for O89100
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3389354905 | 13 | G>D | No | EVA | |
| rs3389378161 | 15 | D>V | No | EVA | |
| rs3389337745 | 23 | D>N | No | EVA | |
| rs3389294690 | 38 | E>G | No | EVA | |
| rs3389294689 | 46 | V>M | No | EVA | |
| rs3389344619 | 80 | F>L | No | EVA | |
| rs3389344617 | 123 | P>T | No | EVA | |
| rs3389294755 | 138 | S>T | No | EVA | |
| rs3389376056 | 148 | G>R | No | EVA | |
| rs3389380557 | 200 | Q>R | No | EVA | |
| rs3389371767 | 213 | P>L | No | EVA | |
| rs3389373166 | 223 | H>Q | No | EVA | |
| rs3389371718 | 227 | R>C | No | EVA | |
| rs3389385594 | 231 | L>M | No | EVA |
No associated diseases with O89100
4 regional properties for O89100
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | SH2 domain | 56 - 149 | IPR000980 |
| domain | SH3 domain | 1 - 56 | IPR001452-1 |
| domain | SH3 domain | 263 - 322 | IPR001452-2 |
| domain | GRAP2, C-terminal SH3 domain | 267 - 319 | IPR035646 |
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| endosome | A vacuole to which materials ingested by endocytosis are delivered. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
1 GO annotations of molecular function
| Name | Definition |
|---|---|
| phosphotyrosine residue binding | Binding to a phosphorylated tyrosine residue within a protein. |
2 GO annotations of biological process
| Name | Definition |
|---|---|
| regulation of MAPK cascade | Any process that modulates the frequency, rate or extent of signal transduction mediated by the MAP kinase (MAPK) cascade. |
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MEATAKFDFM | ASGEDELSFR | TGDILKILSN | QEEWLKAELG | SQEGYVPKNF | IDIEFPEWFH |
| 70 | 80 | 90 | 100 | 110 | 120 |
| EGLSRHQAEN | LLMGKDIGFF | IIRASQSSPG | DFSISVRHED | DVQHFKVMRD | TKGNYFLWTE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| KFPSLNKLVD | YYRTTSISKQ | KQVFLRDGTQ | DQGHRGNSLD | RRSQGGPHPS | GTVGEEIRPS |
| 190 | 200 | 210 | 220 | 230 | 240 |
| VNRKLSDHLP | LGPQQFHPHQ | QPSPQFTPGP | QPPQQQRYLQ | HFHQDRRGGS | LDINDGHCGL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| GSEVNATLMH | RRHTDPVQLQ | AAGRVRWARA | LYDFEALEED | ELGFRSGEVV | EVLDSSNPSW |
| 310 | 320 | ||||
| WTGRLHNKLG | LFPANYVAPM | MR |